スポーツベットアイオー: 円と仮想通貨のベッティング - ブック ...

International Affairs Students Current Students Alumni Faculty/Staff Careers--> TOHOKU UNIVERSITYCREATING GLOBAL EXCELLENCE Search 日本語 Contact Tohoku University --> About Facts & Figures Facilities Organization Chart History President's Message Top Global University Project Designated National University Global Network Promotional Videos Academics Undergraduate Graduate Courses in English Exchange Programs Summer Programs Double Degree Programs Academic Calendar Syllabus Admissions Undergraduate Admissions Graduate Admissions Fees and Expenses Financial Aid Research Feature Highlights Research Releases University Research News Research Institutes Visitor Research Center Research Profiles Academic Research Staff Campus Life International Support Office IT Services Facilities Dining & Shops Campus Bus Clubs & Circles News University News Research--> Arts & Culture Health & Sports Campus & Community Press Release--> International Visit Alumni Careers Events Exhibits Music Special Event Lecture Alumni--> Map & Directions Campus Maps & Bus--> Facilities Map--> TOHOKUUNIVERSITY About Academics Admissions Research Campus Life News Events International Affairs Students Current Students Alumni Faculty/Staff Promotional Videos Subscribe to our Newsletter Map & Directions Contact Jobs & Vacancies Emergency Information Site Map 日本語 Close Home Research News Promising Development for Breast Cancer Patients Research News Promising Development for Breast Cancer Patients 2024-02-19 In a step forward for breast cancer treatment, researchers at Tohoku University have developed a novel monoclonal antibody which specifically targets a certain type of breast cancer cell. Their findings, published in the International Journal of Molecular Sciences, offer a new tool for treating this disease. Breast cancer remains a significant global health concern that afflicts millions of people each year. The HER2-positive subtype of breast cancer is one of the most aggressive and challenging to treat. Approximately 20% of breast cancer cases are classified as HER2-positive, meaning that there is an urgent need for therapies targeted to this specific subtype. A research team led by Yukinari Kato rose to this challenge by developing a monoclonal antibody that precisely targets HER2-positive breast cancer cells. Monoclonal antibodies are specialized proteins engineered to recognize and bind to specific targets with exceptional precision. HER2-positive breast cancer cells have more of the HER2 protein on their surface than healthy cells. This protein plays an important role in cell growth and division, and the excess of HER2 is one reason HER2-positive tumors are aggressive. By specifically targeting HER2-positive cells, the antibody disrupts their growth and proliferation while minimizing harm to surrounding healthy tissue. "The development of this antibody represents a significant milestone in our ongoing efforts to advance breast cancer treatment," says Kato. "By targeting HER2-positive breast cancer cells with precision, we can offer patients a more effective and less toxic treatment option." By specifically targeting HER2-positive cells, the monoclonal antibody inhibits the growth and division of cancerous cells while minimizing damage to adjacent healthy tissue. ©Yukinari Kato et al. The new antibody offers a more targeted and selective approach than conventional treatments, such as chemotherapy, which can cause significant collateral damage to healthy cells. This precision not only enhances the efficacy of treatment but also reduces the incidence and severity of side effects, greatly improving the quality of life of breast cancer patients. The project is set to move to the next phase, which will include clinical trials and regulatory approval processes. The researchers will also explore potential applications of other novel antibodies in various therapeutic areas, assessing whether they can improve outcomes for people battling other types of cancer. The research was supported by grants from the Japan Agency for Medical Research and Development (AMED), including the "Science and Technology Platform Program for Advanced Biological Medicine" and "Basis for Supporting Innovative Drug Discovery and Life Science Research (BINDS)". Publication Details: Title: A Cancer-specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft ModelsAuthors: Mika K. Kaneko, Hiroyuki Suzuki, Tomokazu Ohishi, Takuro Nakamura, Tomohiro Tanaka, and Yukinari KatoJournal: International Journal of Molecular SciencesDOI: 10.3390/ijms25031941 Press release in Japanese Contact: Yukinari Kato, Tohoku University Graduate School of Medicine Email: yukinari.kato.e6tohoku.ac.jpWebsite: https://www.med.tohoku.ac.jp/laboratory/view/9 --> Archives 2014&＃24180; 2015&＃24180; 2016&＃24180; 2017&＃24180; 2018&＃24180; 2019&＃24180; 2020&＃24180; 2021&＃24180; 2022&＃24180; 2023&＃24180; 2024&＃24180; Page Top About Tohoku University Academics Admissions Research Campus Life News Events International Affairs Students Alumni Promotional Videos Subscribe to our Newsletter Map & Directions Contact Tohoku University Jobs & Vacancies Emergency Information Site Map Privacy Policy Media Enquiries Parent & Family Support Public Facilities Contact Tohoku University